118 related articles for article (PubMed ID: 21269981)
1. [Diagnostic value of serum CEACAM1 in patients with pancreatic cancer].
Gong DY; Fu HX; Peng Y; You YQ; Li ZP
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jan; 31(1):164-6. PubMed ID: 21269981
[TBL] [Abstract][Full Text] [Related]
2. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
5. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
7. [The diagnostic value of serum carcinoma markers, fecal K-ras and p53 gene mutation in pancreatic cancers].
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Zhonghua Nei Ke Za Zhi; 2005 Oct; 44(10):741-4. PubMed ID: 16255879
[TBL] [Abstract][Full Text] [Related]
8. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
[TBL] [Abstract][Full Text] [Related]
9. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
10. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic value of serum angiopoietin-2 level in pancreatic cancer].
Wan RG; Chen DB; Lou YG; Wang MF; Zhang QH; Jin DX; Zhou SH
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):47-9. PubMed ID: 21575464
[TBL] [Abstract][Full Text] [Related]
12. Assay of serum CEACAM1 as a potential biomarker for breast cancer.
Yang C; He P; Liu Y; He Y; Yang C; Du Y; Zhou M; Wang W; Zhang G; Wu M; Gao F
Clin Chim Acta; 2015 Oct; 450():277-81. PubMed ID: 26343926
[TBL] [Abstract][Full Text] [Related]
13. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
14. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
15. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
16. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
18. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
19. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]